Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend i

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05%

GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer,

FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expandin

U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembr

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA)

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted ma

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) acc

This donation, along with the additional supply being readied, continues the company's long-stan

Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda

– Novel Investigational Combination Pairs Merck's Islatravir, a Next-Generation Nucleoside Analo

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (N

Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed

Gilead applauds the leadership of the Government of South Africa and the Global Fund for acceleratin

Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization

CONSHOHOCKEN, Pa. [June 2, 2026] — Cencora today announced an agreement with Kite , a Gilead Company

Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive results from a Phase 3 study in people

– ALP Is a Key Marker of Disease Activity in People Living With PBC, With Elevations Above Normal As

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-hepatitis-d

– Recommendation Based on ASCENT-03 Study, Demonstrating Highly Statistically Significant and Clinic

Maxim Group analyst Michael Okunewitch upgrades Gilead Sciences (NASDAQ:GILD) from Hold to Buy an

Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges t

Gilead intends to use the net proceeds from this offering for general corporate purposes, which may

Nasdaq jumps 1.6% to record highs Friday as semiconductor rally and stronger-than-expected April pay

Truist Securities analyst Gregory Renza reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and r

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform

Guidance and OutlookFor the full year 2026, Gilead now expects:(in millions, except per share amount

GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)(unaudited)     (i

GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)(unaudited)     (i

Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $2.03 per share which beat the analyst

Gilead Sciences (NASDAQ: GILD) will release Q1 earnings on May 7, with analysts expecting $1.91 EPS

Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook

Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declin

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have bee

– Additional Commitment will Expand Access to Lenacapavir to Reach Another Million People Over the N

Citigroup analyst Geoff Meacham maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight

Tempus AI (TEM) shares up 3.6% on expanded Gilead oncology deal. Explore technical support levels, A

Gilead expands Tempus AI deal and licenses Kymera's KT-200, advancing oncology pipeline with dat

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision m

KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise

Gilead shares dip after $3.15 billion Tubulis deal adds ADC asset, as multiple acquisitions reshape

https://www.bloomberg.com/news/articles/2026-04-07/gilead-agrees-to-buy-cancer-biotech-tubulis-in-5-